Recent Developments in Patent Rights for Pharmaceuticals in China and India by Hason, Averie K. & Shimotake, Jean E.
Pace International Law Review
Volume 18
Issue 1 Spring 2006 Article 12
April 2006
Recent Developments in Patent Rights for
Pharmaceuticals in China and India
Averie K. Hason
Jean E. Shimotake
Follow this and additional works at: http://digitalcommons.pace.edu/pilr
This Article is brought to you for free and open access by the School of Law at DigitalCommons@Pace. It has been accepted for inclusion in Pace
International Law Review by an authorized administrator of DigitalCommons@Pace. For more information, please contact cpittson@law.pace.edu.
Recommended Citation
Averie K. Hason and Jean E. Shimotake, Recent Developments in Patent Rights for Pharmaceuticals in
China and India, 18 Pace Int'l L. Rev. 303 (2006)
Available at: http://digitalcommons.pace.edu/pilr/vol18/iss1/12
RECENT DEVELOPMENTS IN PATENT
RIGHTS FOR PHARMACEUTICALS IN
CHINA AND INDIA*
Averie K. Hason, Esq.t
and Jean E. Shimotake, Esq.tt
I. Introduction ....................................... 303
A. Background on the TRIPS Agreement ......... 304
B. Patent Rights in China Prior to Recent
Am endm ents .................................. 305
C. Patent Rights in India Prior to Recent
Amendm ents .................................. 306
II. China and India Revise Their Patent Laws to
Comply with TRIPS ............................... 307
A. The 2000 Amendments to China's Patent Law. 308
B. The 2005 Amendments to India's Patent Law . 309
III. Issues in China .................................... 310
A. Challenges Relating to Pharmaceuticals ....... 310
B. Enforcement of Patent Rights in China ........ 312
IV. Issues in India .................................... 313
A. "Mailbox" Applications and Compulsory
Licensing ...................................... 313
V . Conclusion ......................................... 315
I. INTRODUCTION
The World Trade Organization (the 'VTO") seeks to pro-
vide intellectual property protection to its Member States
through the Trade-Related Aspects of Intellectual Property
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Rights agreement (the "TRIPS agreement" or "TRIPS").' The
objective of TRIPS is to protect and enforce intellectual property
rights, contribute to the promotion of technological innovation
and aid in the transfer and dissemination of technology in a
manner conducive to social and economic welfare. 2 China and
India, two countries with historically less-developed patent pro-
tection, recently revised their patent laws to be in compliance
with the WTO. 3 TRIPS introduces intellectual property rules
into the multilateral trading system for the first time.4 This ar-
ticle focuses specifically on the newly-amended patent laws in
China and India and their effects on pharmaceuticals.
A. Background on the TRIPS Agreement
Effective January 1, 1995, the TRIPS agreement requires
its signatories to enact basic patent laws that provide certain
minimum patent protection to inventors of the signatory coun-
try as well as inventors of all WTO Member States. 5 Member
States may implement more extensive protection than is re-
quired by TRIPS.6 TRIPS sets forth the subject matter that is
protected, the rights that are conferred, the permissible excep-
tions to those rights and the minimum duration of the protec-
tion.7 TRIPS states that "patents shall be available for any
inventions, whether products or processes, in all fields of tech-
nology, provided that they are new, involve an inventive step
1 Marrakesh Agreement Establishing the World Trade Organization Annex
1C, Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr.
15, 1994, available at http://www.wto.org/english/docs-e/legal-e/legal-e.htm#
TRIPS (last visited Mar. 23, 2006) [hereinafter TRIPS Agreement].
2 Id. The areas of intellectual property covered by TRIPS are copyright and
related rights; trademarks; geographical indications; industrial designs; patents;
layout-designs (topographies) of integrated circuits; and undisclosed information.
Id. arts. 9-39.
3 See Patent Law of the People's Republic of China (promulgated by the
Standing Comm. of the Ninth Nat'l People's Cong., Aug. 25, 2000, effective July 1,
2001) (P.R.C.), available at http://www.sipo.gov.cnsipo-English/flfg/default.htm
(last visited Apr. 28, 2006); The Patents (Amendment) Act, 2005, No. 15, Acts of
Parliament, 2005 (India).
4 Id.
5 Supra note 1, arts. 1.1, 1.3, 3.1.
6 Id. art. 1.1.
7 World Trade Organization, Intellectual Property, Overview: the TRIPS
Agreement, http://www.wto.org/english/tratope/trips-e/intel2_e.htm (last visited
Mar. 23, 2006).
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and are capable of industrial application."8 WTO Member
States were required to be in compliance with TRIPS by Janu-
ary 1, 2005.9 For this reason, Member States with basic patent
protection that failed to conform with the terms of TRIPS have
recently made significant changes to their patent laws in order
to be TRIPS compliant. 10 Two such member states include the
People's Republic of China ("China") and India.
B. Patent Rights in China Prior to Recent Amendments
Modern patent law in China dates back to 1950 with the
issuance of the Provisional Regulations of the Protection of In-
vention Rights and Patent Rights.11 These regulations pro-
vided patent protection and rewards to inventors, but the
ownership of the inventions remained with the State. 12 During
the Cultural Revolution from 1966 to 1975, the small rewards
granted to inventors were eliminated.1 3
In 1984, China adopted the Patent Law of the People's Re-
public of China.1 4 Article 25 excluded certain classes of items
from patent protection: "(1) scientific discoveries; (2) rules and
methods for mental activities; (3) methods for the diagnosis or
for the treatment of diseases; foods, beverages and flavorings;
(5) pharmaceutical products and substances obtained by means
8 TRIPS Agreement, supra note 1, art. 27.
9 The timeframe in which least-developed countries must be in compliance
with TRIPS was extended from January 1, 2006 to January 1, 2016. See Commis-
sion on Intellectual Property Task Force on TRIPS, Dept. of Policy and Business
Practices, Initial Views on the Post-Doha Agenda of the Council for TRIPS, (June
24, 2002) at 2 http://www.wto.orgenglish/forums-e/ngo-e/icc-trips-e.doc; Nathan
Stacy, The Efficacy and Fairness of Current Sanctions in Effecting Stronger Patent
Rights in Developing Countries, 12 TULSA J. COMP. & INT'L. L. 263, 279-80 (2004).
10 On November 14, 2001, the WTO adopted the Declaration on the TRIPS
Agreement and Public Health in an effort to ensure that WTO Member States im-
plement and interpret the TRIPS Agreement in a way that does not prevent Mem-
bers from taking measures to protect public health. Declaration on the TRIPS
Agreement and Public Health, Nov. 14, 2001, available at http://www.wto.orglen-
glishlthewto e/minist_e/min01_e/mindecl..trips-e.htm (last visited May 10, 2006).
11 The Embassy of the United States, IPR Toolkit, http://beijing.usembassy-
china.org.cn/iprpatent.html (last visited Dec. 30, 2005).
12 Id.
13 Id.
14 Patent Law of the People's Republic of China (promulgated by the Standing
Comm. of the Sixth Nat'l People's Cong., Mar. 12, 1984, effective Apr. 1, 1984)
(P.R.C.), reprinted in ROBERT H. Hu, RESEARCH GUIDE TO CHINESE PATENT LAW
AND PRACTICE, at app. 5 (2002).
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of a chemical process; (6) animal and plant varieties; [and] (7)
substances obtained by means of nuclear transformation." 15
After threat of sanction by the United States Trade Repre-
sentative, the United States and China signed a Memorandum
of Understanding on the Protection of Intellectual Property,
whereby China agreed to revamp its intellectual property pro-
tection. 16 The amendments, put into effect in 1992, omitted the
exclusion from patent protection of pharmaceutical products,
substances obtained by means of a chemical process, and food,
beverages and flavorings, thereby expanding the scope of pro-
tection.17 In addition, the amended laws increased the patent
term for inventions from fifteen to twenty years from the date of
filing an application.' In an effort to conform to the relevant
provisions of TRIPS, China amended its patent law in 2000, ef-
fective July 2001.19
C. Patent Rights in India Prior to Recent Amendments
India's patent law dates back to 1856 with the enactment of
Act VI of 1856 on Protection of Inventions, which is based on
the British Patent Law of 1852.20 Patents were called "exclu-
sive privileges," and were granted fourteen year terms.21 In
1959, the Act was expanded to include protection for designs. 22
15 Id. art. 25; Stacy, supra note 9, at 300-01.
16 Memorandum of Understanding Between the Government of the People's
Republic of China and the Government of the United States of America on the
Protection of Intellectual Property, 1992 reprinted in ROBERT H. Hu, RESEARCH
GUIDE TO CHINESE PATENT LAW AND PRACTICE, at app. 6 (2002); Andrew Evans,
Note, Taming the Counterfeit Dragon: The WTO, TRIPS and Chinese Amendments
to Intellectual Property Laws, 31 GA. J. INT'L & COMP L. 587, 597 (2003).
17 Patent Law (promulgated by the Standing Comm. of the Seventh Nat'l Peo-
ple's Cong., Sept. 4, 1992, effective Dec. 21, 1993) (P.R.C.), reprinted in ROBERT H.
Hu, RESEARCH GUIDE TO CHINESE PATENT LAW AND PRACTICE, at app. 3 (2002).
18 Id. art. 45. For utility models, patent term was extended from five to ten
years. Compare Patent Law, art. 45 (1984) (P.R.C.), with Patent Law, art. 45
(1992) (P.R.C.).
19 Patent Law (2000) (P.R.C.)
20 History of Indian Patent System, http://www.patentoffice.nic.in/ipr/patent/
history.htm (last visited Mar. 23, 2006); Patent Office, India, Manual of Patent
Practice and Procedure 1, 7 (2005), available at http://www.patentoffice.nic.in/ipr/
patent/manual-2052005.pdf.
21 Patent Office, India, Manual of Patent Practice and Procedure 1, 7 (2005),
http://www.patentoffice.nic.in/ipr/patent/manual-2052005.pdf.
22 Id. "'Design' means only the features of shape, configuration, pattern, orna-
ment or composition of lines or colours applied to any article whether in two di-
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Although India had patent laws before the 1900s, formal patent
protection was introduced with the enactment of the Patent Act
of 1911.23
During the middle of the twentieth century, the Indian gov-
ernment appointed two committees-the first in 1949 and the
second in 1957-to review India's patent law and suggest poten-
tial modifications to the law. 24 The 1957 committee's recom-
mendations inspired a Patent Bill that was passed by India's
Parliament and effective as the Patents Act, 1970.25 The 1970
Patent Act provided protection for processes, but did not pro-
vide protection for compositions of matter.26 The term of patent
protection for process patents was seven years from the filing
date of a patent application.27 India revised the 1970 Act in
1999, 2002 and 2005.28
II. CHINA AND INDIA REVISE THEIR PATENT LAWS TO COMPLY
WITH TRIPS
There are three basic requirements for patentability under
the current patent laws of China and India. First, the invention
must be new or novel. 29 Second, the invention must be inven-
tive.30 Specifically, China's patent law requires "inventiveness"
meaning "as compared with the technology existing before the
date of filing of the patent application, the invention has promi-
nent substantive features and represents a notable progress." 31
India's patent law requires an "inventive step," which is defined
mensional or three dimensional or in both forms, by any industrial process or
means, whether manual, mechanical or chemical, separate or combined, which in
the finished article appeal to and are judged solely by the eye .... See The De-
signs Act, 2000, No. 16, art. 2(d), Acts of Parliament, 2000 (India), available at
http://www.patentoffice.nic.in/ipr/designldesign-act.PDF. A utility patent protects
the way an invention is used or works.
23 Rajkumar Dubey, Making it TRIPS Way - India's New Patent Regime,
MONDAQ Bus. BRIEFING, July 18, 2005, available at 2005 WLNR 11268677
(Westlaw).
24 See Manual of Patent Practice and Procedure, supra note 20, at 7.
25 The Patents Act, 1970, No. 39, Acts of Parliament, 1970 (India).
26 Id. § 5.
27 Id. § 53(1).
28 See generally, http://www.patentoffice.nic.in/ipr/patent/patents.htm.
29 See Patent Law, art. 22 (2000) (P.R.C.); The Patents (Amendment) Act,
§ 2(1), 2005 (India).
30 Id.
31 Patent Law, art. 22 (2000) (P.R.C.).
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as "a feature of an invention that involves technical advance as
compared to existing knowledge or having economic significance
or both and that makes the invention not obvious to a person
skilled in the art."32 Lastly, the invention must have a utility.
China's patent law requires "practical applicability," namely,
that the invention "can be made or used and can produce effec-
tive results."33 In India, the patent law requires the "industrial
application" of an invention, meaning that the invention is ca-
pable of being made or used in industry. 34 These basic require-
ments for patentability are just one element of the modern
patent laws of China and India. Substantive revisions, dis-
cussed below, were made to the patent laws of China and India
as part of the requirements for membership in the WTO.
A. The 2000 Amendments to China's Patent Law
China amended its patent law in 2000 in a further effort to
comply with TRIPS and obtain membership into the WTO. 3 5
Some key amendments include changes to the law concerning
the burden of proof in the infringement of process patents and
compulsory licensing.36 The burden of proof with regard to ac-
tions for the infringement of process patents is now shifted to
the alleged infringer.37 This places the onus on the alleged in-
fringer, who presumably is in possession of the relevant facts
regarding potential infringement or lack thereof.38
32 The Patents (Amendment) Act, § 2(a), 2005 (India). For comparative pur-
poses, U.S. patent law requires "non-obviousness": the invention must not have
been obvious to one with ordinary skill in the art to which the subject matter of the
invention pertains at the time of the invention and in light of the teachings of the
prior art. 35 U.S.C. § 103(a).
33 Patent Law, art. 22 (2000) (P.R.C.).
34 The Patents (Amendment) Act, § 3, 2002 (India). In the United States, the
invention must have "utility": it must be useful or perform some function of posi-
tive benefit to society. 35 U.S.C. § 101.
35 On December 11, 2001, China became a member of the WTO. See China's
WTO Achievements Recognized, CHINA DAILY, Dec. 15 2005.
36 A compulsory license is an exception to the exclusive rights granted to pat-
ent owners to prevent third parties not having the patent owner's consent from
making, using, offering for sale, selling, or importing a patented product or product
obtained by a patented process. It allows the Member State to license a patented
product without the authorization of the rights holder. Requirements for compul-
sory license vary among Member States. TRIPS Agreement, supra note 1, art. 34.
37 Patent Law, art. 57 (2000) (P.R.C.).
38 TRIPS Agreement, supra note 1, art. 34; Patent Law, art. 57 (2000)
(P.R.C.).
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Furthermore, the amendments add more stringent condi-
tions for issuing compulsory licenses. 39 Under the amended
law, a party must first request authorization from the inventor
to exploit the patent.40 If such request is denied, the requesting
party may apply for the grant of a compulsory license from the
Patent Administration Department Under the State Council.4 1
The scope and duration of the exploitation must be specified
and the patentee may request the Patent Administration De-
partment Under the State Council terminate the compulsory li-
cense "if and when the circumstances which lead to such
compulsory license cease to exist and are unlikely to recur."42
B. The 2005 Amendments to India's Patent Law
The 2005 revisions to India's patent law expand patent pro-
tection to food, drugs and medicines. 43 Until the 2005 amend-
ments, India's patent law did not provide protection for
pharmaceuticals. 44 As a result, the generic pharmaceutical in-
dustry flourished in India. The amendment expanding patent
protection to pharmaceuticals is the most significant change in
India's modern patent law and will certainly have great impact
on India's position and role in the global pharmaceutical
market.
The amendments also provide for compulsory licensing for
the manufacture and export of pharmaceutical products to any
country having insufficient or no manufacturing capacity of its
own to address public health problems. 45 Before granting a
compulsory license, the government considers whether the ap-
39 Patent Law, arts. 48-55 (2000) (P.R.C.).
40 Patent Law, art. 48 (2000) (P.R.C.). Under the 1984 patent laws, compul-
sory licensing was available upon request to the Patent Office, if the patentee
failed, without any justified reason, to make or use the process or product in China
after three years from the grant of patent right. Id. arts. 51-52.
41 Patent Law, art. 48 (2000) (P.R.C.); Louis Sorell, A Comparative Analysis of
Selected Aspects of Patent Law in China and the United States, 11 PAc. RIM. L. &
POL'Y J. 319, 336 (2002).
42 Patent Law, art. 52 (2000) (P.R.C.); see also Yahong Li, The Wolf Has Come:
Are China's Intellectual Property Industries Prepared for the WTO? 20 UCLA PAC.
BASIN L.J. 77, 86 (2002).
43 The Patents (Amendment) Act, § 5, Acts of Parliament, 2005 (India).
44 Compare The Patents Act, § 5(1), 1970 (India), with The Patents (Amend-
ment) Act, § 5, 2005 (India) (omitting § 5.
45 The Patents (Amendment) Act, § 92A(1), 2005 (India).
20061 309
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plicant has made efforts to obtain a license from the patent
holder for a "reasonable period," defined as a period of six
months. 46 Once this six-month period expires, if the patent
holder refuses to grant a license, the applicant may approach
the government for grant of a compulsory license without the
patent holder's consent.4 7 The compulsory license must be
granted by the country to which the request is made, or such
country must have previously allowed importation of the pat-
ented pharmaceutical from India.48 Notably, these provisions
encourage domestic production and bolster generic pharmaceu-
tical manufacturers. 49
III. ISSUES IN CHINA
A. Challenges Relating to Pharmaceuticals
Historically, copying in China was viewed favorably and
encouraged as a means of disseminating information to all peo-
ple.50 Imitating and copying were seen as forms of flattery.51
With respect to pharmaceuticals, Chinese patent law before the
1992 amendments did not provide patent protection for compo-
sitions of matter.52 Therefore, while the process of making a
compound was patentable, it was not considered infringement
to make the compound using an unpatented process since the
underlying composition was not protected subject matter.53 The
1992 amendments afforded patent protection to pharmaceuti-
cals.54 Even with the added protection for pharmaceuticals,
however, the production, manufacture and sale of counterfeit
46 The Patents (Amendment) Act, § 84(iv), 2005 (India).
47 Id.
48 The Patents (Amendment) Act, § 92A(1), 2005 (India).
49 Rochelle Chodock, TRIPS: Transformation of the Indian Patent System and
Its Effect on the Indian Pharmaceutical Sector, 2 No. 2 ABA ScITECH L. 4 (2005).
50 Evans, supra note 16, at 588-89.
51 Yahong Li, The Wolf Has Come: Are China's Intellectual Property Indus-
tries Prepared for the WTO?, 20 U.C.L.A. PACIFIC BASIN L. J. 77, 93 (2002).
52 Compare Patent Law, art. 25 (1984) (P.R.C.), with Patent Law, art. 25
(1992) (P.R.C.). Article 25 of the 1984 patent law prohibited the granting of patents
directed to pharmaceutical products. However, this prohibition was removed in
the amended 1992 patent law.
53 Patent Law, art. 25 (1984) (P.R.C.).
54 Patent Law, art. 25 (1992) (P.R.C.).
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pharmaceuticals remains a significant issues facing pharma-
ceutical companies. 55
Counterfeit pharmaceuticals deprive brand-name drug
manufacturers of sales and revenue and may potentially harm
consumers. 56 Due to their low cost, counterfeit pharmaceuticals
are attractive to consumers. Lost revenue deprives companies
of resources to invest in pharmaceutical development, innova-
tion and research activities.5 7 Products with sub-quality active
ingredients, no active ingredients or harmful inactive ingredi-
ents emerge in the marketplace along side brand name prod-
ucts, indistinguishable in all other respects. 58
Pharmaceutical companies are taking action to combat
counterfeiters. 59 Companies have developed sophisticated
packaging, logos and structures for their drug products.60
Strategies include holographic labels on packaging, unusually-
shaped products that are difficult to reproduce and labeling the
inside of glass vials. 6 1 In the future, more advanced methods of
deterring counterfeiters are expected.62 The goal is to make
patented products difficult to copy, and if copied, easily recog-
nizable as fakes to both companies and consumers.63
China is taking positive steps toward strengthening protec-
tion of intellectual property and patent rights.64 Not only has
China amended its patent laws to be TRIPS compliant, it has
established a court dedicated to the resolution of patent dis-
putes.65 Founded in October 1996, the No. 3 Civil Division han-
5 Merri C. Moken, Fake Pharmaceuticals: How They and Relevant Legisla-
tion or Lack Thereof Contribute to Consistently High and Increasing Drug Prices,
29 Am. J.L. & MED. 525, 525 (2003).
56 Id. at 531-32.
57 Id. at 532-33.
58 Id. at 527.
59 Id. at 535.
60 Id.
61 Id.
62 Moken, supra note 55, at 536.
63 Id.
64 Chris Buckley, On Piracy, an Advocate for China's Progress, INTrL HERALD
TRIB., Oct. 4, 2005, available at http://www.chinaiprlaw.com/english/forum76.htm.
65 Intellectual Property Courts in China, Judicial Protection of IPR in China:
The organization, functions and powers of the People's Courts, available at http:/!
www.chinaiprlaw.com/english/courts/courtl.htm (last visited Mar. 30, 2006).
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dles intellectual property rights cases. 66 This Intellectual
Property division hears approximately 100-200 intellectual
property right cases per year.67
B. Enforcement of Patent Rights in China
There are three routes of enforcement of patent rights of
China: administrative, judicial and criminal. 6 The law allows
for negotiation and settlement of patent disputes.69 If settle-
ment between the parties fails, an aggrieved patentee may in-
stitute legal proceedings in the People's Court or the party may
request the Patent Affairs Administration to assist in settling
the matter via an administrative route. 70 Under the adminis-
trative route, damages include confiscation of the illegal income
of the infringer, a fine of no more than three times the illegal
income and/or a discretionary fine where there is no illegal
income.' 1
A party may also pursue the judicial route. A cardinal prin-
ciple of China's judicial system is independent judicial power in
accordance with the law. There is no court precedent and no
case law system.7 2 Moreover, judges are authorized to cite to
laws and regulations but are prohibited from citing to facts. 73
Therefore, similar facts may result in different judgments by
different courts.7 4 There is a risk that this may lead to inconsis-
tent application of the law and unpredictability.
In the event the infringement constitutes a crime, the pat-
ent holder may seek criminal prosecution under the Criminal
66 See Judicial Protection of IPR in China: Enforcement of Intellectual Prop-
erty Law in Post-WTO China, http://www.chinaiprlaw.com/english/forum/forum40.
htm (last visited Mar. 31, 2006). The No. 3 Civil Division was formerly called the
Intellectual Property Division. Id.
67 See Judicial Protection of IPR in China: Enforcement of Intellectual Prop-
erty Law in Post-WTO China, http://www.chinaiprlaw.com/english/forum/forum69.
htm (last visited May 12, 2006).
68 Patent Law, arts. 57-58 (2000) (P.R.C.).
69 Id. art. 57.
70 Id. The Patent Affairs Administration has concurrent jurisdiction with the
People's Court over patent infringement actions. Id. art. 3.
71 Id. art. 58.
72 Sorell, supra note 41, at 330-31.
73 Id. at 331.
74 Id.
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Law of the People's Republic of China.75 Criminal punishment
for counterfeiting is minimal: imprisonment of not more than
three years, and/or a fine. 76
IV. ISSUES IN INDIA
A. "Mailbox" Applications and Compulsory Licensing
When India acceded to the WTO in January 1995, it agreed
to bring its patent laws into compliance with TRIPS within ten
years from the day it was accepted into the WTO. 77 At that
time, India's patent law did not protect compositions of matter.
Knowing that by 2005 the necessary legal framework would ex-
ist under which composition of matter applications could be ex-
amined, India established a patent office "mailbox" into which
patent applications for products were deposited.7 8 The patent
office held the applications for examination until after revised
patent laws were promulgated.7 9 Now that the laws have been
enacted, the applications are being removed from the mailbox
and reviewed in the order in which they were deposited.8 0 The
patent term for mailbox patents will be calculated from the date
of deposit.8 1
The delay between the deposit of an application in the pat-
ent office mailbox and the issuance of the patent has conse-
quences on the ability of the patent owner to institute
infringement actions.8 2 A patentee cannot institute a patent in-
fringement action against an entity or company that has been
75 Criminal Law (promulgated by the Standing Comm. of the Fifth Nat'l Peo-
ple's Cong., July 1, 1979, revised Mar. 14, 1997), art. 216 (P.R.C.), available at
http://www.cecc.gov/pages/newLaws/criminalLawENG.php.; Interpretation by the
Supreme People's Court and the Supreme People's Procuratorate on Several Issues
of Concrete Application of Laws in Handling Criminal Cases of Infringing Intellec-
tual Property (promulgated by the 13th Sess. of the Jud. Comm. of the Supreme
People's Ct., Nov. 2, 2004, and the 28th Sess. of the Tenth Procuratorial Comm. of
the Supreme People's Procuratorate, Nov. 11, 2004, effective Dec. 22, 2004), art.
10, available at http://www.chinaiprlaw.com/english/laws/laws20.htm(P.R.C.).
76 Criminal Law, art. 216 (1979) (P.R.C.).
77 See Frederick M. Abbott, The WTO Medicines Decision: World Pharmaceu-
tical Trade and the Protection of Public Health, 99 AM. J. INT'L. L. 317, 320 (2005).
78 Id. at 321.
79 Id.
80 Id. at 320 n.24.
81 Id. at 321.
82 See Chodock, supra note 49, at 5.
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producing and manufacturing a patented product before 2005
and who continues to manufacture the product on the date of
the patent grant.8 3 Typically, the infringer is a generic drug
manufacturer that manufactured the now-patented product
while the patent application for the product sat in the
mailbox.84 This provision is essentially a compulsory license to
the manufacturer. The only remedy available to the patent
holder is a reasonable royalty.85
The 2005 Amendments to the Patent Laws and a Shift To-
ward Innovation and Outsourcing
Currently, more than twenty percent of the world's generic
pharmaceuticals are produced in India.8 6 With the recent
changes to India's patent laws, the historically generic pharma-
ceutical companies will likely shift their focus toward innova-
tion. As there is a shift toward innovation, research and
development outsourcing will become an important issue.8 7
Manufacturing costs are estimated to be fifty percent below
manufacturing costs in Europe and the United
States.88 Moreover, India has the largest number of U.S. FDA-
approved plants outside the United States and Indian manufac-
turers are now required to be compliant with Good Manufactur-
ing Practices.8 9 In contrast to its historic position, India's
current patent system supports innovation and the protection of
patent rights while simultaneously protecting the dominant ge-
neric market.
83 Id.
84 Id.
85 The Patents (Amendment) Act, § 11A, Acts of Parliament, 2005 (India);
Manisha Singh, India's Patent Law - is it TRIPS Compliant?, MANAGING INTEL-
LECTUAL PROPERTY, July 1, 2005, at 67; Elizabeth Engdahl, India Alters Patent
Views: The New Law Looks More Innovation Friendly and Mostly TRIPS-Compli-
ant, LEGAL TIMES 56, July 11, 2005, at 56, 58.
86 India Set For Solid Growth in Pharmaceutical Industry, Says New PwC
Report, PHARMA MARKETLETTER, Aug. 1, 2005, available at 2005 WLNR 12162024
(Westlaw).
87 Eric Bellman, India Senses Patent Appeal; Local Companies Envision Bene-
fits in Stronger Protection, WALL ST. J. (Eastern Ed.), Apr. 11, 2005.
88 See Chodock, supra note 49, at 4.
89 Eric Ladley, Patent Reform Has Global Effect, MED AD NEWS, May 1, 2005,
available at 2005 WLNR 8860450 (Westlaw).
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V. CONCLUSION
China and India are actively globalizing their patent sys-
tems through compliance with the international standards of
TRIPS. However, with China's relatively short patent law his-
tory and fractured judicial system, the risk of counterfeiting
and the difficulty with patent enforcement remain decisive fac-
tors in companies' considerations as to whether to make and
sell patented pharmaceuticals in China. In India, it remains to
be seen how the newly-created patent protection for
pharmaceuticals will be enforced in a country that until now
has thrived on the generic pharmaceutical industry.
13
